Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Presents Data on Complement Component 5-targeting Drug

Premium

Alnylam Pharmaceuticals last week released preclinical data on ALN-CC5, an RNAi-based drug targeting complement component 5 and the newest addition to its product-development pipeline.

The complement system is involved in immunity as a protective mechanism for host defense, according to the company. Dysregulation of the system can create serious complications in a variety of diseases including paroxysmal nocturnal hemoglobinuria, atypical hemolytic-uremic syndrome, myasthenia gravis, and neuromyelitis optica.

Complement component C5, which is primarily expressed in liver cells, is a validated target whose loss is associated with an “attenuated immune response” against certain infections, Alnylam added.

The company said that its preclinical data shows that ALN-CC5 can trigger dose-dependent and durable RNAi-mediated knockdown of serum C5 and inhibition of complement-mediated hemolytic activity of approximately 90 percent after subcutaneous administration.

“Specifically, a prototype GalNAc-siRNA conjugate targeting C5 showed a single dose ED50 for C5 knockdown of approximately 0.6 mg/kg in rodent models,” Alnylam said. “In multi-dose experiments, subcutaneous administration of the GalNAc-siRNA conjugate resulted in approximately 90 percent knockdown of serum C5 levels at doses [at or greater than] 1.25 mg/kg.”

Additionally, in multi-dose experiments, the company’s lead drug candidate achieved about 90 percent inhibition of complement-mediated hemolytic activity in the rat at subcutaneous doses of 5 mg/kg.

The data were presented at the International Conference on Complement Therapeutics held earlier this month in Greece.

Alnylam expects to nominate its ALN-CC5 candidate before the end of this year.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.